Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Long-term survival, quality-adjusted survival, and cost-effectiveness analysis

James, N; Woods, B; Sideris, E; Spears, MR; Dearnaley, DP; Mason, M; Clarke, N; ... Sculpher, M; + view all James, N; Woods, B; Sideris, E; Spears, MR; Dearnaley, DP; Mason, M; Clarke, N; Parmar, MKB; Sydes, MR; Sculpher, M; - view fewer (2018) Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Long-term survival, quality-adjusted survival, and cost-effectiveness analysis. In: Figlin, Robert and Spielberg, Steven, (eds.) Proceedings of the 2018 Genitourinary Cancers Symposium. American Society of Clinical Oncology (ASCO): San Francisco, CA, USA.

http://bit.ly/2ASgV0H